Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2024; 16(7): 2888-2893
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.2888
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.2888
Maximizing therapeutic outcomes in hepatocellular carcinoma: Insights into combinatorial strategies
Yusuf Ilhan, Yakup Ergun, Department of Medical Oncology, Antalya City Hospital, Antalya 07080, Türkiye
Author contributions: Ilhan Y reviewed the literature and wrote the manuscript; Ergun Y contributed to the discussion and design of the manuscript. All authors reviewed, edited, and approved the final manuscript and revised it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.
Conflict-of-interest statement: The authors declare that there are no potential conflicts of interest with respect to the research, authorship, and publication of the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yakup Ergun, MD, Department of Medical Oncology, Antalya City Hospital, Gocerler neighborhood, 5379 Street, Antalya 07080, Türkiye. dr.yakupergun@gmail.com
Received: March 1, 2024
Revised: April 18, 2024
Accepted: April 30, 2024
Published online: July 15, 2024
Processing time: 133 Days and 7.7 Hours
Revised: April 18, 2024
Accepted: April 30, 2024
Published online: July 15, 2024
Processing time: 133 Days and 7.7 Hours
Core Tip
Core Tip: Combining transarterial chemoembolization (TACE) with tyrosine kinase inhibitors and immune checkpoint inhibitors shows promise in enhancing therapeutic outcomes for hepatocellular carcinoma (HCC) patients, offering viable alternatives when TACE alone is ineffective or unsuitable. Further exploration and validation of these combination therapies with TACE, as well as investigating other local treatment options for potential synergistic effects, are warranted to optimize HCC treatment strategies.